Zogenix sold the Zohydro franchise to Pernix; AbbVie got its hands on Imbruvica through the $20 billion takeover of Pharmacyclics. Biopharma financing reached a six-month high in March, while in medtech the total was a six-month low.
Exhibit 1
Top Alliances In March 2015
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy
Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.
In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.
